PMID-41545261 – Tesamorelin Body Composition Meta-Analysis
Badran AS, et al. Effects of tesamorelin on body composition in adults: a systematic review and meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026.
Quick Reference
| Property | Value |
|---|---|
| PMID | 41545261 |
| DOI | Pending |
| Year | 2026 |
| Journal | Obesity Research and Clinical Practice |
| Study Type | Meta-analysis |
| Evidence Level | I (Oxford CEBM) |
| Sample | Meta-analysis of 5 RCTs |
| Peptide(s) Studied | Tesamorelin |
Key Findings
- Pooled analysis of 5 RCTs demonstrated tesamorelin produces a mean reduction of -27.71 cm2 in visceral adipose tissue (VAT) versus placebo
- Hepatic fat fraction decreased by a mean of -4.28% compared to placebo across included trials
- Lean body mass increased by a mean of +1.42 kg, indicating anabolic benefit alongside fat reduction
- The dual effect of visceral fat reduction and lean mass preservation represents a favorable body composition profile not seen with many weight loss interventions
- Results were consistent across studies, supporting robust efficacy of tesamorelin for metabolic body composition improvement
- The meta-analysis provides the highest level of evidence (Level I) for tesamorelin's effects on body composition
Study Design
Systematic review and meta-analysis following PRISMA guidelines. Searched PubMed, Embase, and Cochrane databases for randomized controlled trials evaluating tesamorelin versus placebo on body composition outcomes. Five RCTs met inclusion criteria. Primary outcomes were changes in visceral adipose tissue, hepatic fat fraction, and lean body mass. Random-effects models were used for pooled analyses. Heterogeneity was assessed using I2 statistics. Risk of bias was evaluated using the Cochrane Risk of Bias tool.
Limitations
- Limited to 5 RCTs, reflecting the relatively small evidence base for tesamorelin
- Most included studies enrolled HIV-infected populations, limiting generalizability to the general population
- Heterogeneity in treatment duration and dosing protocols across studies
- Publication bias could not be fully excluded given the small number of studies
- Long-term sustainability of body composition changes after tesamorelin discontinuation not well-addressed in pooled data
Clinical Relevance
This meta-analysis provides the most comprehensive quantitative summary of tesamorelin's effects on body composition to date. The specific numbers (-27.71 cm2 VAT, -4.28% hepatic fat, +1.42 kg lean mass) offer clinicians concrete expected outcomes for patient counseling. The simultaneous reduction in visceral/hepatic fat with lean mass preservation distinguishes tesamorelin from caloric-restriction-based approaches and positions it as a valuable component of metabolic optimization and GH-axis protocols. These data directly support tesamorelin's inclusion in the GH Optimization Protocol and Weight Management strategies.
Related
#research #meta-analysis #evidence-level-I #tesamorelin #metabolic